Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, MD, PhD, Wael A. Harb, MD, Brian T. Hill, MD, PhD, Janice Gabrilove, MD, Jeff P. Sharman, MD, Marshall T. Schreeder, MD, MPH, Paul M. Barr, MD, James M. Foran, MD, Thomas P. Miller, MD, Jan A. Burger, MD, PhD, Kevin R. Kelly, MD, PhD, Daruka Mahadevan, MD, PhD, Shuo Ma, MD, PhD, Evelyn Barnett, Jeffrey Marine, Pilar Nava-Parada, Ada Azaryan, Jay Mei, MD, Thomas J. Kipps, MD, PhD

Blood (2013) 122 (21): 1630.

https://doi.org/10.1182/blood.V122.21.1630.1630

Published: 2013

Journal Articles

Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

Thomas Prebet, M.D., Ph.D., Steven D. Gore, M.D., Zhuoxin Sun, PhD, Peter L. Greenberg, MD, Mark Juckett, MD, Lisa Malick, Mitchell R Smith, MD, PhD, Elisabeth Paietta, PhD, Magdalena Czader, Janice Gabrilove, M.D., Harry P Erba, DM, PhD, Martin S. Tallman, MD

Blood (2010) 116 (21): 601.

https://doi.org/10.1182/blood.V116.21.601.601

Published: 2010

Journal Articles

Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL

Mark C Lanasa, MD, PhD, Leslie Andritsos, MD, Jennifer R Brown, MD, PhD, Janice Gabrilove, M.D., Federico Caligaris-Cappio, M.D., Richard Larson, M.D., Thomas J. Kipps, MD, PhD, Veronique Leblond, M.D., Donald Milligan, MD, FRCP, FRCPath, Ann Janssens, M.D., Nyla A. Heerema, Ph.D., Stephan Stilgenbauer, M.D., John C. Byrd, MD, Michael R. Grever, M.D.

Blood (2010) 116 (21): 58.

https://doi.org/10.1182/blood.V116.21.58.58

Published: 2010

Journal Articles

A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study

Thomas Prebet, M.D., Ph.D., Zhuoxin Sun, PhD, Rhett Ketterling, Gary Hicks, Ph.D., C.L. Beach, PharmD, Peter L. Greenberg, MD, Elisabeth Paietta, PhD, Magdalena Czader, M.D., Ph.D., Janice Gabrilove, M.D., Harry P Erba, DM, PhD, Martin S. Tallman, MD, Steven D. Gore, M.D.

Blood (2010) 116 (21): 4013.

https://doi.org/10.1182/blood.V116.21.4013.4013

Published: 2010

Journal Articles

Clofarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities.

Stefan Faderl, MD, Harry P Erba, David F. Claxton, M.D., M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Elizabeth Anderson, Elly Barry, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 4155.

https://doi.org/10.1182/blood.V114.22.4155.4155

Published: 2009

Journal Articles

Outpatient Treatment with Clofarabine in a Phase II Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia (AML).

David F. Claxton, M.D., Thomas J Myers, MD, FACP, Harry P Erba, Stefan Faderl, MD, M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Clay R Warnock, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 4162.

https://doi.org/10.1182/blood.V114.22.4162.4162

Published: 2009

Journal Articles

A Pilot Feasibility Study Assessing the Role of Scheduled Sleep Intervention in Improving Fatigue in Cancer Patients After Completion of Chemotherapy for Hematological Malignancy.

Nouneh Gostanian, MD, Joshua Bauml, MD, Marisa Cortese, RN, MS, FNP, BC, Paul Greene, PhD, William Redd, PhD, Janice Gabrilove, MD

Blood (2009) 114 (22): 4546.

https://doi.org/10.1182/blood.V114.22.4546.4546

Published: 2009

Journal Articles

Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors.

Janice Gabrilove, MD, Stefan Faderl, MD, Harry P Erba, David F. Claxton, M.D., M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Stephen Eckert, Ph.D, Dirk Huebner, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 2061.

https://doi.org/10.1182/blood.V114.22.2061.2061

Published: 2009

Journal Articles

Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are ≥ 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.

Harry P Erba, Stefan Faderl, MD, David F. Claxton, M.D., M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Stephen Eckert, Ph.D, Dirk Huebner, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 2083.

https://doi.org/10.1182/blood.V114.22.2083.2083

Published: 2009

Journal Articles

Arsenic Trioxide Plus ABT-737 Is Synergistic to Induce Apoptosis in AML Cells by Repression of Mcl-1 Protein and Inactivation of Bcl-2 Protein

Lijuan Xia, Rui Wang, Hao Qian, Janice Gabrilove, MD, Samuel Waxman, MD, Yongkui Jing, PhD

Blood (2008) 112 (11): 2653.

https://doi.org/10.1182/blood.V112.11.2653.2653

Published: 2008

Journal Articles

A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium

Lewis R. Silverman, MD, Amit Verma, Rosalie Odchimar-Reissig, Amanda LeBlanc, Vesna Najfeld, Janice Gabrilove, Luis Isola, Igor Espinoza-Delgado, MD, James Zwiebel

Blood (2008) 112 (11): 3656.

https://doi.org/10.1182/blood.V112.11.3656.3656

Published: 2008

Journal Articles

Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine

Hagop Kantarjian, MD, Frank Giles, MD, Peter Greenberg, MD, Ronald Paquette, MD, Eunice Wang, MD, Janice Gabrilove, MD, Guillermo Garcia-Manero, MD, Julie Gray, Kuolung Hu, PhD, Janet Franklin, MD, MPH

Blood (2008) 112 (11): 224.

https://doi.org/10.1182/blood.V112.11.224.224

Published: 2008

Journal Articles

Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy

Harry Paul Erba, MD, PhD, Hagop Kantarjian, David F. Claxton, MD, M. Arellano, Roger M Lyons, MD, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Stephen Eckert, Ph.D, Rekha Abichandani, MD, Stefan Faderl, MD

Blood (2008) 112 (11): 558.

https://doi.org/10.1182/blood.V112.11.558.558

Published: 2008

Journal Articles

The Efficacy and Safety of Darbepoetin Alfa for Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Results after 53/55 Weeks.

Janice Gabrilove, MD, Ronald Paquette, MD, Roger M. Lyons, MD, Chaudhry Mushtaq, MD, Mikkael A. Sekeres, MD, Hung Lam, PhD, Lyndah Dreiling, PhD

Blood (2006) 108 (11): 2671.

https://doi.org/10.1182/blood.V108.11.2671.2671

Published: 2006

Journal Articles

A Phase 2, Single-Arm, Open-Label Trial To Evaluate the Effectiveness of Darbepoetin alfa for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndrome.

Janice Gabrilove, Ron Paquette, Roger Lyons, Chaudhry Mushtaq, Mikkael Sekeres, Hung Lam, Lyndah Dreiling

Blood (2005) 106 (11): 2541.

https://doi.org/10.1182/blood.V106.11.2541.2541

Published: 2005

Journal Articles

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

Eileen Scigliano, MD, Celia Grosskreutz, MD, Steven Fruchtman, MD, Janice Gabrilove, MD, John Mandeli, PhD, Luis Isola, MD

Blood (2005) 106 (11): 5315.

https://doi.org/10.1182/blood.V106.11.5315.5315

Published: 2005

Journal Articles

Recombinant Methionyl Human Stem Cell Factor and Filgrastim for Peripheral Blood Progenitor Cell Mobilization and Transplantation in Non-Hodgkin's Lymphoma Patients — Results of a Phase I/II Trial

Craig H. Moskowitz, Patrick Stiff, Michael S. Gordon, Ian McNiece, Anthony D. Ho, John J. Costa, E. Randolf Broun, Robert A. Bayer, Melody Wyres, Jerome Hill, Kathy Jelaca-Maxwell, Craig R. Nichols, Sherri L. Brown, Stephen D. Nimer, Janice Gabrilove

Blood (1997) 89 (9): 3136–3147.

https://doi.org/10.1182/blood.V89.9.3136

Published: 1997

NARROW

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL

A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study

Clofarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities.

Outpatient Treatment with Clofarabine in a Phase II Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia (AML).

A Pilot Feasibility Study Assessing the Role of Scheduled Sleep Intervention in Improving Fatigue in Cancer Patients After Completion of Chemotherapy for Hematological Malignancy.

Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors.

Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are ≥ 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.

Arsenic Trioxide Plus ABT-737 Is Synergistic to Induce Apoptosis in AML Cells by Repression of Mcl-1 Protein and Inactivation of Bcl-2 Protein

A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium

Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine

Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy

The Efficacy and Safety of Darbepoetin Alfa for Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Results after 53/55 Weeks.

A Phase 2, Single-Arm, Open-Label Trial To Evaluate the Effectiveness of Darbepoetin alfa for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndrome.

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

Recombinant Methionyl Human Stem Cell Factor and Filgrastim for Peripheral Blood Progenitor Cell Mobilization and Transplantation in Non-Hodgkin's Lymphoma Patients — Results of a Phase I/II Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only